Reviewing Hillstream Biopharma (NASDAQ:CNTN) and Acerus Pharmaceuticals (OTCMKTS:ASPCF)

Acerus Pharmaceuticals (OTCMKTS:ASPCF) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Acerus Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Hillstream Biopharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Acerus Pharmaceuticals and Hillstream Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acerus Pharmaceuticals	0	0	0	0	0.00
Hillstream Biopharma	1	0	0	0	1.00

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Hillstream Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	$2.12 million	0.80	-$33.82 million	($3.57)	-0.06
Hillstream Biopharma	N/A	N/A	-$35.92 million	($1.15)	-1.77

Acerus Pharmaceuticals has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acerus Pharmaceuticals and Hillstream Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	-924.33%	N/A	-74.62%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Summary

Hillstream Biopharma beats Acerus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.